{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:50Z","timestamp":1792783490875,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40121-016-0107-0","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T02:46:27Z","timestamp":1460774787000},"page":"89-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Meningococcal Vaccinations"],"prefix":"10.1007","volume":"5","author":[{"given":"Nancy","family":"Crum-Cianflone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"107_CR1","doi-asserted-by":"crossref","unstructured":"Stephens DS, Apicella MA. Neisseria meningitidis. In: Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. 8th ed. Philadelphia, PA Elsevier Saunders Inc.; 2015. p. 2425-45.","DOI":"10.1016\/B978-1-4557-4801-3.00213-7"},{"key":"107_CR2","first-page":"59","volume":"5","author":"E Marchiafava","year":"1884","unstructured":"Marchiafava E, Celli A. Spra i micrococchi della meningite cerebrospinale epidemica. Gazz degli Ospedali. 1884;5:59.","journal-title":"Gazz degli Ospedali."},{"key":"107_CR3","first-page":"573","volume":"5","author":"A Weichselbaum","year":"1887","unstructured":"Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebrospinalis. Fortschr Med. 1887;5:573.","journal-title":"Fortschr Med"},{"key":"107_CR4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853\u201361.","journal-title":"Lancet Infect Dis."},{"key":"107_CR5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstin MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327\u201348.","journal-title":"J Exp Med"},{"key":"107_CR6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","journal-title":"J Exp Med"},{"key":"107_CR7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(98)00279-7","volume":"353","author":"DS Stephens","year":"1999","unstructured":"Stephens DS. Uncloaking the meningococcus, the dynamics of meningococcal carriage and meningococcal disease. Lancet. 1999;353:941\u20132.","journal-title":"Lancet"},{"key":"107_CR8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378\u201388.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"107_CR9","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3\u20139.","journal-title":"Vaccine."},{"key":"107_CR10","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","volume":"24","author":"MP Girard","year":"2006","unstructured":"Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692\u2013700.","journal-title":"Vaccine."},{"key":"107_CR11","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","volume":"364","author":"MC Thigpen","year":"2011","unstructured":"Thigpen MC, Whitney CG, Messonnier NE, et al. Emerging infections programs network. bacterial meningitis in the United States, 1998\u20132007. N Engl J Med. 2011;364:2016\u201325.","journal-title":"N Engl J Med"},{"key":"107_CR12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/CMR.00070-09","volume":"23","author":"MC Brouwer","year":"2010","unstructured":"Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467\u201392.","journal-title":"Clin Microbiol Rev"},{"key":"107_CR13","unstructured":"WHO Initiative for Vaccine Research (IVR): Meningococcal disease. Available at http:\/\/www.who.int\/vaccine_research\/diseases\/soa_bacterial\/en\/index1.html . Accessed 1 Feb 2016."},{"key":"107_CR14","unstructured":"Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521\u201339."},{"key":"107_CR15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33:737\u20139.","journal-title":"Clin Infect Dis"},{"key":"107_CR16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-3476(81)80250-8","volume":"99","author":"MS Edwards","year":"1981","unstructured":"Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99:540\u20135.","journal-title":"J Pediatr"},{"key":"107_CR17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14787210.2015.1070096","volume":"13","author":"E Gianchecchi","year":"2015","unstructured":"Gianchecchi E, Torelli A, Piccini G, Piccirella S, Montomoli E. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther. 2015;13:1249\u201363.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"107_CR18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/JCM.17.5.722-727.1983","volume":"17","author":"FE Ashton","year":"1983","unstructured":"Ashton FE, Ryan A, Diena B, et al. A new serogroup (L) of Neisseria meningitidis. J Clin Microbiol. 1983;17:722\u20137.","journal-title":"J Clin Microbiol"},{"key":"107_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-1157(81)80056-X","volume":"9","author":"S Ding","year":"1981","unstructured":"Ding S, Ye R, Zhang H. Three new serogroups of Neisseria meningitidis. J Biol Stand. 1981;9:305\u201315.","journal-title":"J Biol Stand."},{"key":"107_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1179\/2047773213Y.0000000119","volume":"107","author":"A Abio","year":"2013","unstructured":"Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107:373\u201380.","journal-title":"Pathog Glob Health."},{"key":"107_CR21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","volume":"31","author":"CL Trotter","year":"2007","unstructured":"Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31:101\u20137.","journal-title":"FEMS Microbiol Rev"},{"issue":"Suppl 2","key":"107_CR22","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","volume":"30","author":"SA Halperin","year":"2012","unstructured":"Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26\u201336.","journal-title":"Vaccine."},{"issue":"Suppl 2","key":"107_CR23","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51\u201363.","journal-title":"Vaccine."},{"key":"107_CR24","volume-title":"Surveillance of Invasive bacterial diseases in Europe 2008\/2009","author":"European Centre for Disease Prevention and Control","year":"2011","unstructured":"European Centre for Disease Prevention and Control. Surveillance of Invasive bacterial diseases in Europe 2008\/2009. Stockholm: ECDC; 2011."},{"key":"107_CR25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","volume":"60","author":"SN Ladhani","year":"2015","unstructured":"Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578\u201385.","journal-title":"Clin Infect Dis"},{"key":"107_CR26","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1016\/j.ijid.2012.03.011","volume":"16","author":"M Ceyan","year":"2012","unstructured":"Ceyan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration. Int J Infect Dis. 2012;16:e574\u201382.","journal-title":"Int J Infect Dis."},{"key":"107_CR27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1017\/S0950268812001689","volume":"141","author":"MA S\u00e1fadi","year":"2012","unstructured":"S\u00e1fadi MA, Gonz\u00e1lez-Ayala S, J\u00e4kel A, et al. The epidemiology of meningococcal disease in Latin America, 1945\u20132010: an unpredictable and changing landscape. Epidemiol Infect. 2012;141:447\u201358.","journal-title":"Epidemiol Infect"},{"key":"107_CR28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0950268811000574","volume":"139","author":"A Vyse","year":"2011","unstructured":"Vyse A, Wolter JM, Chen J, et al. Meningococcal disease in Asia: an under-recognised public health burden. Epidemiol Infect. 2011;139:967\u201385.","journal-title":"Epidemiol Infect"},{"key":"107_CR29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","volume":"71","author":"J Lucidarme","year":"2015","unstructured":"Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544\u201352.","journal-title":"J Infect."},{"key":"107_CR30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","volume":"34","author":"MM Mustapha","year":"2016","unstructured":"Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970\u20132015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515\u201323.","journal-title":"Vaccine."},{"key":"107_CR31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3201\/eid1909.130160","volume":"19","author":"H Zhou","year":"2013","unstructured":"Zhou H, Liu W, Xu L, et al. Spread of Neisseria meningitidis serogroup W clone, China. Emerg Infect Dis. 2013;19:1496\u20139.","journal-title":"Emerg Infect Dis."},{"key":"107_CR32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cit243","volume":"57","author":"S Mandal","year":"2013","unstructured":"Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344\u20138.","journal-title":"Clin Infect Dis"},{"key":"107_CR33","first-page":"606","volume":"64","author":"HM Soeters","year":"2015","unstructured":"Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college\u2014Rhode Island, 2015. MMWR. 2015;64:606\u20137.","journal-title":"MMWR."},{"key":"107_CR34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.idc.2015.08.002","volume":"29","author":"A Cohn","year":"2015","unstructured":"Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin N Am. 2015;29:667\u201377.","journal-title":"Infect Dis Clin N Am"},{"key":"107_CR35","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease: Technical & Clinical Information. http:\/\/www.cdc.gov\/meningococcal\/clinical-info.html . Accessed 20 Feb 2016."},{"key":"107_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","volume":"31","author":"DS Stephens","year":"2007","unstructured":"Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31:3\u201314.","journal-title":"FEMS Microbiol Rev"},{"key":"107_CR37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","volume":"80","author":"DM Mutonga","year":"2009","unstructured":"Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005\u20132006. Am J Trop Med Hyg. 2009;80:619\u201324.","journal-title":"Am J Trop Med Hyg"},{"key":"107_CR38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"S Ram","year":"2010","unstructured":"Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740\u201380.","journal-title":"Clin Microbiol Rev"},{"key":"107_CR39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clim.2012.09.007","volume":"145","author":"EC Miller","year":"2012","unstructured":"Miller EC, Chase NM, Densen P, et al. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and neisserial sepsis: c4 nephritic factor revisited. Clin Immunol. 2012;145:241\u201350.","journal-title":"Clin Immunol."},{"key":"107_CR40","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","volume":"13","author":"GH Struijk","year":"2013","unstructured":"Struijk GH, Bouts AHM, Rijkers GT, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819\u201320.","journal-title":"Am J Transplant"},{"key":"107_CR41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/archinte.1981.00340050110026","volume":"141","author":"IE Salit","year":"1981","unstructured":"Salit IE. Meningococcemia caused by serogroup W-135: association with hypogammaglobulinemia. Arch Intern Med. 1981;141:664\u20135.","journal-title":"Arch Intern Med"},{"key":"107_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/P14-9011","volume":"160","author":"L Miller","year":"2014","unstructured":"Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014;160:30\u20137.","journal-title":"Ann Intern Med"},{"issue":"4","key":"107_CR43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/0003-4819-159-4-201308200-00674","volume":"159","author":"MS Simon","year":"2013","unstructured":"Simon MS, Weiss D, Gulick RM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159(4):300\u20131.","journal-title":"Ann Intern Med"},{"key":"107_CR44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(03)00740-0","volume":"3","author":"M Emonts","year":"2003","unstructured":"Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis. 2003;3:565\u201377.","journal-title":"Lancet Infect Dis."},{"key":"107_CR45","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(98)08350-0","volume":"353","author":"ML Hibberd","year":"1999","unstructured":"Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet. 1999;353:1049\u201353.","journal-title":"Lancet"},{"key":"107_CR46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2249.2000.01208.x","volume":"120","author":"CA Fijen","year":"2000","unstructured":"Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defense against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol. 2000;120:338\u201345.","journal-title":"Clin Exp Immunol"},{"key":"107_CR47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","volume":"50","author":"AC Cohn","year":"2010","unstructured":"Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184\u201391.","journal-title":"Clin Infect Dis"},{"key":"107_CR48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.286.6.688","volume":"286","author":"MG Bruce","year":"2001","unstructured":"Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688\u201393.","journal-title":"JAMA"},{"key":"107_CR49","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1\u201328."},{"key":"107_CR50","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1128\/JCM.43.9.4811-4814.2005","volume":"43","author":"JJ Sejvar","year":"2005","unstructured":"Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43:4811\u20134.","journal-title":"J Clin Microbiol"},{"key":"107_CR51","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3201\/eid0808.010422","volume":"8","author":"J-F Aguilera","year":"2002","unstructured":"Aguilera J-F, Perrocheau A, Meffre C. Hahn\u00e9 S; W135 Working Group. Outbreak of the serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8:761\u20137.","journal-title":"Emerg Infect Dis"},{"key":"107_CR52","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/j.vaccine.2007.04.032","volume":"25","author":"R Teyssou","year":"2007","unstructured":"Teyssou R, Muros-Le RE. Meningitis epidemics in Africa: a brief overview. Vaccine. 2007;25:A3\u20137.","journal-title":"Vaccine."},{"key":"107_CR53","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.1990.03450100061026","volume":"264","author":"PS Moore","year":"1990","unstructured":"Moore PS, Hierholzer J, DeWitt W, Gouan K, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningoccal meningitis. JAMA. 1990;264:1271\u20135.","journal-title":"JAMA"},{"key":"107_CR54","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00006454-199710000-00015","volume":"16","author":"M Fischer","year":"1997","unstructured":"Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979\u201383.","journal-title":"Pediatr Infect Dis J."},{"key":"107_CR55","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3201\/eid0910.030182","volume":"9","author":"AM Molesworth","year":"2003","unstructured":"Molesworth AM, Cuevas LE, Connor SJ, et al. Environmental risk and meningitis epidemics in Africa. Emerge Infect Dis. 2003;9:1287\u201393.","journal-title":"Emerge Infect Dis."},{"key":"107_CR56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(85)90812-8","volume":"2","author":"BM Greenwood","year":"1985","unstructured":"Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet. 1985;2:829\u201330.","journal-title":"Lancet"},{"key":"107_CR57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","volume":"282","author":"MS Artenstein","year":"1970","unstructured":"Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282:417\u201320.","journal-title":"N Engl J Med"},{"key":"107_CR58","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","volume":"30","author":"C Vipond","year":"2012","unstructured":"Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30:B10\u20137.","journal-title":"Vaccine."},{"key":"107_CR59","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1365-3156.2012.03085.x","volume":"17","author":"R Borrow","year":"2012","unstructured":"Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health. 2012;17:1478\u201391.","journal-title":"Trop Med Int Health"},{"key":"107_CR60","doi-asserted-by":"crossref","first-page":"19077","DOI":"10.1073\/pnas.1314476110","volume":"1110","author":"F Micoli","year":"2013","unstructured":"Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA. 2013;1110:19077\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"107_CR61","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","volume":"50","author":"DM Granoff","year":"2010","unstructured":"Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50:S54\u201365.","journal-title":"Clin Infect Dis"},{"key":"107_CR62","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","volume":"9","author":"J Holst","year":"2013","unstructured":"Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9:1241\u201353.","journal-title":"Hum Vaccin Immunother."},{"key":"107_CR63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","volume":"11","author":"F Caron","year":"2011","unstructured":"Caron F, du Ch\u00e2telet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455\u201363.","journal-title":"Lancet Infect Dis."},{"key":"107_CR64","first-page":"608","volume":"64","author":"T Folaranmi","year":"2015","unstructured":"Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608\u201312.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"107_CR65","doi-asserted-by":"crossref","unstructured":"Kim DK, Bridges CB, Harriman KH, on behalf of the Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164:184\u201394.","DOI":"10.7326\/M15-3005"},{"key":"107_CR66","unstructured":"Australian Immunisation Handbook. Australian Government Department of Health. 4.10 Meningococcal disease. Available at http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/Handbook10-home~handbook10part4~handbook10-4-10#list4-10-1 . Accessed 21 Feb 2016."},{"key":"107_CR67","unstructured":"Joint Committee on Vaccination and Immunisation. Available at https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation . Accessed 21 Feb 2016."},{"key":"107_CR68","unstructured":"Green Book: Chapter 7 Immunization of Individuals with Underlying Medical Conditions; p. 49\u201356. Available at https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/309218\/Green_Book_Chapter_7_v1_3.pdf . Chapter 22 Meningococcal; p. 1\u201329. Available at https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/462629\/2904512_Green_Book_Chapter_22_v6_0W.PDF . Chapter 12 Immunisation of healthcare and laboratory staff; p. 83\u201390. Available at https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147882\/Green-Book-Chapter-12.pdf ."},{"key":"107_CR69","unstructured":"Geretti AM; BHIVA Immunization Writing Committee. British HIV Association guidelines for immunization of HIV-infected adults 2015. British HIV Association 2015. Available at http:\/\/www.bhiva.org\/documents\/Guidelines\/Vaccination\/2015-Vaccination-Guidelines.pdf ."},{"key":"107_CR70","unstructured":"Public Agency of Canada-Canada Immunization Guide. Available at www.publichealth.gc.ca . Accessed 21 Feb 2016."},{"key":"107_CR71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MC Maiden","year":"2008","unstructured":"Maiden MC, Ibarza-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343.","journal-title":"J Infect Dis"},{"key":"107_CR72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","volume":"383","author":"DM Daugla","year":"2014","unstructured":"Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40\u20137.","journal-title":"Lancet"},{"key":"107_CR73","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1093\/cid\/civ592","volume":"61","author":"J-M Okwo-Bele","year":"2015","unstructured":"Okwo-Bele J-M, LaForce FM, Borrow R, Preziosi M-P. Documenting the results of a successful partnership: a new meningococcal vaccine for Africa. Clin Infect Dis. 2015;61:S389\u201390.","journal-title":"Clin Infect Dis"},{"key":"107_CR74","unstructured":"WHO Weekly epidemiological record-Meningococcal A conjugate vaccine: updated guidance, February 2015;90, 57\u201368. Available at http:\/\/www.who.int\/wer\/2015\/wer9008.pdf?ua=1 ."},{"key":"107_CR75","first-page":"52","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. Infant meningococcal vaccination: advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"107_CR76","doi-asserted-by":"crossref","unstructured":"Al-Tawfiq JA, Memish ZA. The Hajj: updated health hazards and current recommendations for 2012. Euro Surveill. 2012;17. pii: 20295.","DOI":"10.2807\/ese.17.41.20295-en"},{"key":"107_CR77","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/QCO.0b013e3283574c06","volume":"25","author":"JP Cramer","year":"2012","unstructured":"Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25:507\u201317.","journal-title":"Curr Opin Infect Dis."},{"key":"107_CR78","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0264-410X(00)00317-0","volume":"19","author":"R Borrow","year":"2000","unstructured":"Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2000;19:1129\u201332.","journal-title":"Vaccine."},{"key":"107_CR79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/315284","volume":"181","author":"P Richmond","year":"2000","unstructured":"Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181:761\u20134.","journal-title":"J Infect Dis"},{"key":"107_CR80","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","volume":"64","author":"JR MacNeil","year":"2015","unstructured":"MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"107_CR81","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","volume":"135","author":"LA McNamara","year":"2015","unstructured":"McNamara LA, Shumate AM, Johnsen P, et al. Use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798\u2013804.","journal-title":"Pediatrics"},{"key":"107_CR82","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(14)60226-9","volume":"383","author":"AJ Pollard","year":"2014","unstructured":"Pollard AJ, Riordan A, Ramsay M. Group B meningococcal vaccine: recommendations for UK use. Lancet. 2014;383:1103\u20134.","journal-title":"Lancet"},{"key":"107_CR83","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu LM, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573\u201382.","journal-title":"JAMA"},{"key":"107_CR84","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Esposito S, Prymula R, et al. EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825\u201335.","journal-title":"Lancet"},{"key":"107_CR85","unstructured":"Vaccine Schedule. The European Centre for Disease Prevention and Control. Available at: http:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx . Accessed on 4 Jan 2016."},{"key":"107_CR86","doi-asserted-by":"crossref","unstructured":"Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20. pii: 21188.","DOI":"10.2807\/1560-7917.ES2015.20.28.21188"},{"key":"107_CR87","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/14760584.2015.979799","volume":"14","author":"MA Safadi","year":"2015","unstructured":"Safadi MA, Bettinger JA, Moreno Meturana G, et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14:505\u201317.","journal-title":"Expert Rev Vaccines"},{"key":"107_CR88","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","volume":"201","author":"LH Harrison","year":"2010","unstructured":"Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era\u2014United States, 2000\u20132005. J Infect Dis. 2010;201:1208\u201324.","journal-title":"J Infect Dis"},{"key":"107_CR89","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1542\/peds.2014-1383","volume":"134","author":"Academy of Pediatrics Committee on Infectious Diseases","year":"2014","unstructured":"Academy of Pediatrics Committee on Infectious Diseases. Updated recommendations on the use of meningococcal vaccines. Pediatrics. 2014;134:400.","journal-title":"Pediatrics"},{"key":"107_CR90","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","volume":"72","author":"P Balmer","year":"2004","unstructured":"Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun. 2004;72:332\u20137.","journal-title":"Infect Immun"},{"key":"107_CR91","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","volume":"161","author":"J Lujan-Zilbermann","year":"2012","unstructured":"Lujan-Zilbermann J, Warshaw MG, Williams PL, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161:676\u201381.","journal-title":"J Pediatr"},{"key":"107_CR92","unstructured":"American Academy of Pediatrics. [Meningococcal Infections.] In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village: American Academy of Pediatrics; 2015. p. 547\u201357."},{"key":"107_CR93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000930","volume":"35","author":"R Gasparini","year":"2016","unstructured":"Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35:81\u201393.","journal-title":"Pediatr Infect Dis J."},{"key":"107_CR94","unstructured":"Food and Drug Administration. Product approval information: package insert. Menactra (meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Sanofi Pasteur. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm131170.pdf . Accessed 21 Feb 2016."},{"key":"107_CR95","unstructured":"Centers for Disease Control and Prevention: Recommended Immunization Schedules for Persons Aged 0 Through 18 years; United States 2016. Available at: http:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/child\/0-18yrs-child-combined-schedule.pdf . Accessed 22 Feb 2016."},{"key":"107_CR96","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2010.11.057","volume":"29","author":"WM Weston","year":"2011","unstructured":"Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29:1017\u201322.","journal-title":"Vaccine."},{"key":"107_CR97","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/hv.27739","volume":"10","author":"YC Zahlanie","year":"2014","unstructured":"Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo S. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995\u20131007.","journal-title":"Hum Vaccin Immunother"},{"key":"107_CR98","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","volume":"21","author":"P Velentgas","year":"2012","unstructured":"Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21:1350\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"107_CR99","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1086\/533469","volume":"46","author":"P Wals De","year":"2008","unstructured":"De Wals P, Deceuninck G, Boucher RM, Ouakki M. Risk of Guillain-Barr\u00e8 syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. Clin Infect Dis. 2008;46:e75\u20137.","journal-title":"Clin Infect Dis."},{"key":"107_CR100","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2013.02.027","volume":"208","author":"Y Zheteyeva","year":"2013","unstructured":"Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol. 2013;208:e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"107_CR101","unstructured":"Toxnet [Internet]. Bethesda (MD): National Library of Medicine (US): [Last Revision Date Mar 10, 2015]. Meningococcal Vaccines; LactMed Record Number: 168 [about 3 p]. Available at: http:\/\/toxnet.nlm.nih.gov\/cgi-bin\/sis\/search2\/r?dbs+lactmed:@term+@DOCNO+168 ."},{"key":"107_CR102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.1976.03260290019018","volume":"235","author":"Anonymous","year":"1976","unstructured":"Anonymous. Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. JAMA. 1976;235:261\u20135.","journal-title":"JAMA."},{"key":"107_CR103","doi-asserted-by":"crossref","unstructured":"Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011; CD004785.","DOI":"10.1002\/14651858.CD004785.pub4"},{"key":"107_CR104","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMcp063561","volume":"355","author":"P Gardner","year":"2006","unstructured":"Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med. 2006;355:1466\u201373.","journal-title":"N Engl J Med"},{"key":"107_CR105","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/JCM.43.7.3162-3171.2005","volume":"43","author":"JH Jorgensen","year":"2005","unstructured":"Jorgensen JH, Crawford SA, Fiebelkorn KR. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005;43:3162\u201371.","journal-title":"J Clin Microbiol"},{"key":"107_CR106","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.rmed.2007.06.030","volume":"101","author":"K Prasad","year":"2007","unstructured":"Prasad K, Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med. 2007;101:2037\u201343.","journal-title":"Respir Med"},{"key":"107_CR107","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jama.1937.02780170025009","volume":"108","author":"FF Schwentker","year":"1937","unstructured":"Schwentker FF, Gelman S, Long PH. The treatment of meningococcal meningitis with sulfonamide: preliminary report. JAMA. 1937;108:1407\u20138.","journal-title":"JAMA"},{"key":"107_CR108","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1517\/14656566.2012.724399","volume":"13","author":"SH Shin","year":"2012","unstructured":"Shin SH, Kim KS. Treatment of bacterial meningitis: an update. Exp Opin Pharmacother. 2012;13:2189\u2013206.","journal-title":"Exp Opin Pharmacother."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-016-0107-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:45:00Z","timestamp":1655495100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-016-0107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s40121-016-0107-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}